These real-world data should reassure clinicians prescribing tirzepatide while we await the results of the SURPASS-CVOT trial evaluating cardiovascular outcomes with this agent.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE OR PATIENT CARE: In obese adults, older than 40 years, with T2DM, and prior ischemic heart disease, treatment with tirzepatide was associated with a lower risk of the combined risk of acute myocardial infarction, stroke, and all-cause mortality than GLP-1 agonists. Here, GLP1R is linked to Stroke.